SECTOR: CHEMICALS
Aarti Industries Limited
STOCK INFO.
BLOOMBERG
BSE Sensex:25,779
S&P CNX:7,843
ARTO:IN
REUTERS CODE
30 September 2015
Initiating Coverage
(INR CRORES)
Buy
INR516
ARTI.NS
Y/E MARCH
Revenue
EBITDA
EBITDA Margin
NP (Adj.)
EPS (Adj.)
EPS Growth
BV/share
Core ROE (%)
Core ROCE (%)
P/E (x)
P/BV (x)
FY15
2,908
466
16.0%
209
23.6
29%
115
22
17
21.8
4.5
FY16E
2,980
562
18.9%
257
30.8
23%
144
23
18
16.7
3.6
FY17E
3,454
684
19.8%
333
39.9
29%
174
25
21
12.9
3.0
KEY FINANCIALS
Diluted Shares (cr)
Market Cap. (Rs cr)
Market Cap. (US$ m)
Past 3 yrs Sales Growth (%)
Past 3 yrs NP Growth (%)
8.3
4,593
695
18%
26%
STOCK DATA
52-W High/Low Range (INR)
Major Shareholders
(as of 28nd September 2015)
Promoter
Institutions
Public & Others
Average Daily Turnover(6 months)
Volume
Value (Rs cr)
1/6/12 Month Rel. Performance (%)
1/6/12 Month Abs. Performance (%)
525/232
59.1
13.3
27.6
94,598
3.6
23/65/86
20/59/82
We recommend to BUY Aarti Industries Ltd (AIL) for a target
of INR 630- valuing the company on SOTP basis.
De-merger to be value accretive:
Company plans to demerge its
three business verticals: (a) specialty chemicals, (b) pharma API and
(c) home & personal care chemicals, and list each separately. This
will help re-rate the specialty chemicals business (EBIT margin of 16-
19%) as well as pharma API (Revenue CAGR 2013-15: 27%).
Pharma is a high-margin and potential high-growth business in a nascent
stage. Most of the investment in pharma facilities is already complete
and the segment broke even in FY12. Now, incremental volumes would
only contribute to expansion in segment margins and ROE.
Geared for growth with global leadership in Speciality
Chemicals:
AIL has a strong understanding of chlorine derivative
chemistry and has the largest nitro-chlorobenzene capacity in India.
Exports account for 51% of speciality chemicals division. It offers
over 100+ products to MNCs globally(globally ranks 1st -5th for most
of its key products) having end-user applications in polymers, additives,
pigments, paints, dyes, agro chemicals, etc to 800+ clients. It has a
"Strategic Supplier" status with many MNCs due to its wider product
portfolio, cost competitiveness and ability to supply consistently. The
Indian Speciality Chemical Industry is expected to reach $60-70bn by
2020 from $23bn in 2013. Aarti Industries should gain from this growth
given its strong customer linkages and command over Chlorine
chemistry.
Capex to lead to revenue growth as well as margin expansion:
The company is looking to expand capacities across benzene, toluene
& ethylene, and nitro toluene based value chain with a capex of ~INR
500cr over the next 3yrs (~asset turnover of 3-4 times) to cater growing
end-user markets and space vacated by closing down of few capacities
in developed markets & reduced global supplies from China. The
company is expected to have firm off-take commitments from global
agrochemical majors for exclusive supply. The addition of value added
products will further aid in margin expansion over the next 3yrs.
Valuations & View:
As a diversified specialty chemicals company,
AIL is a play on two key emerging trends: (1) rising demand for specialty
chemicals in India (15% CAGR FY15-FY20E) and (2) eastward
migration of global chemical manufacturing (Asia to have 70%
production share by 2030). We believe Aarti Industries is available at
attractive valuations of 9.6x FY17E EBITDA. Our SOTP based price
target for Aarti Industries is at INR 630 providing for an upside of
22%.
Maximum Buy Price :INR540
Ravi Shenoy (ravi.shenoy@MotilalOswal.com); Tel: +91 22 30896865